Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 636

1.

Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2010 Jul-Aug;16(6):402-16. Review.

PMID:
20635831
[PubMed - indexed for MEDLINE]
Free Article
2.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

PMID:
17083854
[PubMed - indexed for MEDLINE]
Free Article
3.

Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.

Croxtall JD.

Drugs. 2011 Sep 10;71(13):1733-53. doi: 10.2165/11207530-000000000-00000. Review.

PMID:
21902296
[PubMed - indexed for MEDLINE]
4.

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

PMID:
22843208
[PubMed - indexed for MEDLINE]
5.

Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.

Scanlon JV, Exter BP, Steinberg M, Jarvis CI.

Ann Pharmacother. 2009 Sep;43(9):1456-65. doi: 10.1345/aph.1M151. Epub 2009 Aug 11. Review.

PMID:
19671802
[PubMed - indexed for MEDLINE]
6.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

PMID:
16948890
[PubMed - indexed for MEDLINE]
Free Article
7.

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11. Review.

PMID:
21910698
[PubMed - indexed for MEDLINE]
8.

Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis.

Fisher VS.

J Manag Care Pharm. 2005 Jan-Feb;11(1):33-55. Review.

PMID:
15667232
[PubMed - indexed for MEDLINE]
Free Article
9.

Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials.

Farhi D.

Drugs Today (Barc). 2010 Apr;46(4):259-64. doi: 10.1358/dot.2010.46.4.1464839.

PMID:
20502723
[PubMed - indexed for MEDLINE]
10.

Golimumab for the treatment of psoriatic arthritis.

Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N.

Health Technol Assess. 2011 May;15 Suppl 1:87-95. doi: 10.3310/hta15suppl1/10. Review.

PMID:
21609657
[PubMed - indexed for MEDLINE]
Free Article
11.

Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.

Doan QV, Chiou CF, Dubois RW.

J Manag Care Pharm. 2006 Sep;12(7):555-69. Review.

PMID:
16981801
[PubMed - indexed for MEDLINE]
Free Article
12.

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

Croxtall JD.

Am J Clin Dermatol. 2012 Apr 1;13(2):135-7. doi: 10.2165/11208650-000000000-00000.

PMID:
22201419
[PubMed - indexed for MEDLINE]
13.

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A.

Ann Rheum Dis. 2011 May;70(5):755-9. doi: 10.1136/ard.2010.139725. Epub 2010 Dec 27.

PMID:
21187298
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Ustekinumab for the treatment of psoriasis.

Laws PM, Warren RB.

Expert Rev Clin Immunol. 2011 Mar;7(2):155-64. doi: 10.1586/eci.11.4. Review.

PMID:
21426253
[PubMed - indexed for MEDLINE]
15.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

PMID:
17049139
[PubMed - indexed for MEDLINE]
Free Article
16.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group.

Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30.

PMID:
24482301
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.

Navarro-Millán I, Singh JA, Curtis JR.

Clin Ther. 2012 Apr;34(4):788-802.e3. doi: 10.1016/j.clinthera.2012.02.014. Epub 2012 Mar 22. Review.

PMID:
22444783
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Ustekinumab for the treatment of moderate to severe psoriasis.

Gospodarevskaya E, Picot J, Cooper K, Loveman E, Takeda A.

Health Technol Assess. 2009 Oct;13 Suppl 3:61-6. doi: 10.3310/hta13suppl3/10. Review.

PMID:
19846031
[PubMed - indexed for MEDLINE]
Free Article
19.

Tocilizumab for rheumatoid arthritis.

Singh JA, Beg S, Lopez-Olivo MA.

Cochrane Database Syst Rev. 2010 Jul 7;(7):CD008331. doi: 10.1002/14651858.CD008331.pub2. Review.

PMID:
20614469
[PubMed - indexed for MEDLINE]
20.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators.

Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4. Erratum in: Lancet. 2008 May 31;371(9627):1838.

PMID:
18486739
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk